A099430 Stock Overview
Engages in the research and development, production, and sale of bio products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Bio Plus Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩8,040.00 |
| 52 Week High | ₩8,390.00 |
| 52 Week Low | ₩4,250.00 |
| Beta | 0.60 |
| 1 Month Change | 10.14% |
| 3 Month Change | 16.69% |
| 1 Year Change | 25.43% |
| 3 Year Change | 7.20% |
| 5 Year Change | n/a |
| Change since IPO | -0.89% |
Recent News & Updates
Bio Plus' (KOSDAQ:099430) Anemic Earnings Might Be Worse Than You Think
Mar 31
Does Bio Plus (KOSDAQ:099430) Have A Healthy Balance Sheet?
Feb 14Recent updates
Bio Plus' (KOSDAQ:099430) Anemic Earnings Might Be Worse Than You Think
Mar 31Does Bio Plus (KOSDAQ:099430) Have A Healthy Balance Sheet?
Feb 14Bio Plus Co., Ltd's (KOSDAQ:099430) Shares Climb 30% But Its Business Is Yet to Catch Up
Jan 07Bio Plus (KOSDAQ:099430) Is Reinvesting At Lower Rates Of Return
Dec 15Bio Plus Co., Ltd's (KOSDAQ:099430) Shareholders Might Be Looking For Exit
Nov 23Earnings Not Telling The Story For Bio Plus Co., Ltd (KOSDAQ:099430) After Shares Rise 29%
Jul 23The Returns On Capital At Bio Plus (KOSDAQ:099430) Don't Inspire Confidence
Jul 05More Unpleasant Surprises Could Be In Store For Bio Plus Co., Ltd's (KOSDAQ:099430) Shares After Tumbling 31%
Jun 08Additional Considerations Required While Assessing Bio Plus' (KOSDAQ:099430) Strong Earnings
Mar 26Shareholder Returns
| A099430 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | 21.5% | 5.7% | 6.5% |
| 1Y | 25.4% | -20.8% | -7.2% |
Return vs Industry: A099430 exceeded the KR Medical Equipment industry which returned -20.8% over the past year.
Return vs Market: A099430 exceeded the KR Market which returned -7.2% over the past year.
Price Volatility
| A099430 volatility | |
|---|---|
| A099430 Average Weekly Movement | 7.7% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in KR Market | 12.6% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A099430 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A099430's weekly volatility (8%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 102 | Hyun-Kyu Jung | www.bioplus.co.kr |
Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms.
Bio Plus Co., Ltd Fundamentals Summary
| A099430 fundamental statistics | |
|---|---|
| Market cap | ₩467.42b |
| Earnings (TTM) | ₩14.15b |
| Revenue (TTM) | ₩66.41b |
33.0x
P/E Ratio7.0x
P/S RatioIs A099430 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A099430 income statement (TTM) | |
|---|---|
| Revenue | ₩66.41b |
| Cost of Revenue | ₩23.87b |
| Gross Profit | ₩42.53b |
| Other Expenses | ₩28.38b |
| Earnings | ₩14.15b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 243.41 |
| Gross Margin | 64.05% |
| Net Profit Margin | 21.31% |
| Debt/Equity Ratio | 36.2% |
How did A099430 perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield20%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/16 00:54 |
| End of Day Share Price | 2025/04/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bio Plus Co., Ltd is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Hanwha Investment & Securities Co., Ltd. |
| Junghyun Kim | Kyobo Securities Co., Ltd |
| Jaehee Won | Shinhan Investment Corp. |